FDA Grants Priority Review To Vioxx For Osteoarthritis And Pain
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Grants Priority Review To Vioxx For Osteoarthritis And Pain

WEST POINT, PA -- Jan. 11, 1999 -- The United States Food and Drug Administration has assigned a six-month priority review to Merck & Co., Inc.’s new drug application for Vioxx(TM) (rofecoxib), an investigational COX-2 specific inhibitor for osteoarthritis and pain.

Merck submitted the application for Vioxx on Nov. 23, 1998.

The application for Vioxx includes results from 68 studies involving nearly 10,000 patients. Those studies evaluated the safety and efficacy of the once-daily, anti-inflammatory medicine for the treatment of the signs and symptoms of osteoarthritis and for the relief of pain.

COX-2 specific inhibitors are being studied to determine whether the apparent differences in how they work may result in fewer certain serious gastrointestinal side effects than nonsteroidal anti-inflammatory drugs, which are medications that are currently available for the treatment of osteoarthritis and pain.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities